Peak Bio, Inc.

Peak Bio, Inc. (Nasdaq: PKBO) is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies, operating within the healthcare and life sciences sector. The company became publicly listed through a SPAC business combination in 2021 and filed its 10-Q quarterly report with the SEC on November 15, 2021, under accession number 0001206774-21-002746, reflecting its status as a newly public operating company in the post-merger period. As a de-SPAC entity in the biotech space, Peak Bio represented the broader trend of clinical-stage therapeutics companies accessing public markets through blank-check vehicle transactions during that cycle. For full filing history, deal structure details, and real-time SPAC analytics on PKBO, sign up for a SpacDesk account at spacdesk.com.